接受特定益生菌制剂治疗的HIV-1感染受试者粪便水样的抗病毒活性

Antiviral Activity of Fecal Water Samples from HIV-1 Infected Subjects Treated with a Specific Probiotic Formulation.

作者信息

Falasca Francesca, Cavallari Eugenio Nelson, Innocenti Giuseppe Pietro, Scagnolari Carolina, Mezzaroma Ivano, Santinelli Letizia, Ceccarelli Giancarlo, Vullo Vincenzo, Turriziani Ombretta, d'Ettorre Gabriella

机构信息

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

出版信息

Curr HIV Res. 2019;17(3):183-189. doi: 10.2174/1570162X17666190903230622.

DOI:10.2174/1570162X17666190903230622

PMID:31490760

Abstract

OBJECTIVES

The aim of the study was to investigate if the supplementation with multistrain probiotics may be able to modulate T cell response in HIV-1 infected patients and to evaluate the anti-HIV activity of probiotic by studying fecal water (FW) samples.

METHODS

Three HIV-1-positive patients (Pt1, Pt2 and Pt3) on long-term suppressive combined antiretroviral therapy (cART) received a specific multi-strain probiotic supplementation (Vivomixx ®), for six months (T6). Levels of T cell subsets were evaluated by flow cytometry. Anti- HIV activity of FW samples was evaluated in vitro.

RESULTS

CD4+ T cells levels increased in all HIV-1 infected patients whereas activation markers (CD38 and HLA-DR) were decreased both on CD4+ and CD8+ T cells. FW samples presented an increased inhibitory activity against HIV-1 compared to T0 (FW-Pt1: T0 =40%, T6 = 65% of reduction; FW Pt2: T0 = 26%, T6 = 46% of reduction; FW Pt3: T0 = 47%, T6 = 94% of reduction).

DISCUSSION

Our data suggest that the administration of the specific probiotic formulation improves the antiviral status of people living with HIV-1 under cART, also modulating T cell response.

CONCLUSION

Anti-HIV activity of FW may have several public health and social implications for sexually transmitted diseases that need to be further explored.

摘要

目的

本研究旨在调查补充多菌株益生菌是否能够调节HIV-1感染患者的T细胞反应，并通过研究粪便水（FW）样本评估益生菌的抗HIV活性。

方法

三名接受长期抑制性联合抗逆转录病毒疗法（cART）的HIV-1阳性患者（Pt1、Pt2和Pt3）接受了特定的多菌株益生菌补充剂（Vivomixx®），为期六个月（T6）。通过流式细胞术评估T细胞亚群的水平。体外评估FW样本的抗HIV活性。

结果

所有HIV-1感染患者的CD4+T细胞水平均升高，而CD4+和CD8+T细胞上的激活标志物（CD38和HLA-DR）均降低。与T0相比，FW样本对HIV-1的抑制活性增加（FW-Pt1：T0时降低40%，T6时降低65%；FW Pt2：T0时降低26%，T6时降低46%；FW Pt3：T0时降低47%，T6时降低94%）。